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Objective: Although the presymptomatic stages of frontotemporal dementia (FTD) provide a unique chance to delay
or even prevent neurodegeneration by early intervention, they remain poorly deﬁned. Leveraging a large multicenter
cohort of genetic FTD mutation carriers, we provide a biomarker-based stratiﬁcation and biomarker cascade of the
likely most treatment-relevant stage within the presymptomatic phase: the conversion stage.Methods: We longitudinally assessed serum levels of neuroﬁlament light (NfL) and phosphorylated neuroﬁlament heavy (pNfH) in the Genetic
FTD Initiative (GENFI) cohort (n = 444), using single-molecule array technique. Subjects comprised 91 symptomatic
and 179 presymptomatic subjects with mutations in the FTD genes C9orf72, GRN, or MAPT, and 174 mutationnegative within-family controls.
Results: In a biomarker cascade, NfL increase preceded the hypothetical clinical onset by 15 years and concurred with
brain atrophy onset, whereas pNfH increase started close to clinical onset. The conversion stage was marked by
increased NfL, but still normal pNfH levels, while both were increased at the symptomatic stage. Intra-individual change
rates were increased for NfL at the conversion stage and for pNfH at the symptomatic stage, highlighting their respective
potential as stage-dependent dynamic biomarkers within the biomarker cascade. Increased NfL levels and NfL change
rates allowed identiﬁcation of presymptomatic subjects converting to symptomatic disease and capture of proximity-toonset. We estimate stage-dependent sample sizes for trials aiming to decrease neuroﬁlament levels or change rates.
Interpretation: Blood NfL and pNfH provide dynamic stage-dependent stratiﬁcation and, potentially, treatment
response biomarkers in presymptomatic FTD, allowing demarcation of the conversion stage. The proposed biomarker
cascade might pave the way towards a biomarker-based precision medicine approach to genetic FTD.
ANN NEUROL 2022;91:33–47

F

rontotemporal dementia (FTD) is a devastating neurodegenerative disease characterized by progressive decline of
executive, behavioral, and language functions,1–3 frequently
resulting from mutations in the genes C9orf72, GRN, and
MAPT.4–8 The presymptomatic stages of genetic FTD might
provide a unique opportunity to delay or even prevent neurodegeneration by early therapeutic intervention, with promising targeted molecular therapies now entering clinical
trials.9,10 However, these presymptomatic stages – which
encompass the accumulation of progressive molecular and
cellular changes in the nervous system before the onset of
dementia – remain poorly deﬁned.11 To pave the way for
future interventional trials, stratiﬁcation of the presymptomatic stages based on objective and easily accessible
biomarkers is hence urgently needed. This applies particularly
to the conversion stage, which immediately precedes the
onset of clinically manifest disease and is the likely most
treatment-relevant stage in the presymptomatic period.
We here propose blood levels of neuroﬁlament light
(NfL) and phosphorylated neuroﬁlament heavy (pNfH) as
objective and easily accessible biomarkers for stratifying the
presymptomatic period of genetic FTD, providing a

temporal cascade of their biomarker changes. Neuroﬁlaments are neuron-speciﬁc cytoskeletal proteins, released
upon neuronal damage and, with ultra-sensitive single molecule array (Simoa) assays, reliably quantiﬁable in peripheral
blood.12–14 Previous work indicated that NfL blood levels
are increased at the symptomatic stage of FTD15 and also in
temporal proximity to the clinical onset of genetic FTD.16
Similarly, also pNfH blood levels might allow capturing
neuronal disintegration and particularly axonal damage, possibly reﬂecting other features of the neurodegenerative process than NfL.12,14 Leveraging a large multicenter cohort of
genetic FTD mutation carriers, we here test the hypothesis
that – in the biomarker cascade of genetic FTD – the conversion stage is demarcated by increased levels of NfL, but
still normal levels of pNfH, whereas the symptomatic stage
is marked by increased levels of both neuroﬁlament types.

Methods
Cohort
Subjects were recruited by the Genetic FTD Initiative
(GENFI), an international consortium with 25 study sites
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across Europe and Canada. Subjects were patients with
FTD caused by mutations in the genes C9orf72, GRN, or
MAPT (symptomatic mutation carriers) and their ﬁrstdegree relatives (ie, either noncarriers serving as controls
or presymptomatic mutation carriers).17 Following the
GENFI protocol, subjects underwent comprehensive
annual assessments, including neurological and neuropsychological examination, brain imaging, and blood collection, as previously described in detail.17 For the present
study, we included all GENFI subjects with at least one
serum sample available (n = 444; sample collection = 2015–2019). In total, our study included 444 subjects (thereof 117 C9orf72, 104 GRN, and 49 MAPT
carriers, and 174 controls), 196 of whom had longitudinal
samples (50 C9orf72, 48 GRN, and 20 MAPT carriers,
and 78 controls; see Table 1 for cohort details, stratiﬁed
by clinical state and gene).
Our study cohort comprises a subset of subjects
(41%) also included in a previous GENFI study16
(n = 184, hereof 79 presymptomatic, 31 symptomatic,
and 4 converting carriers, and 70 controls). Accordingly,
blood samples from 388 (52%) of the 748 study visits
from which blood samples were assessed in our study were
also included in this previous study, but now independently measured.
Local ethics committees at each site approved the
study. All subjects provided written informed consent
prior to participation according to the Declaration of
Helsinki.
Mutation carriers were considered symptomatic if
fulﬁlling established diagnostic criteria for FTD, including
behavioral variant FTD and primary progressive aphasia
phenotypes.1,2 C9orf72 mutation carriers were also considered symptomatic if fulﬁlling established criteria for
amyotrophic lateral sclerosis (ALS),18 but not FTD. Those
mutation carriers who were presymptomatic at baseline
but became symptomatic during follow-up are referred to
as converters (6 C9orf72 and 1 GRN carriers). Disease
severity was assessed with the Clinical Dementia Rating
scale plus FTLD modules (CDR plus NACC FTLD),
using the global score.19 As the symptomatic stage can
alternatively also be deﬁned by mutation carriers having a
CDR plus NACC FTLD score ≥1, we also ran the main
analyses with this criterion. Clinical raters were blinded to
the genetic status of at-risk individuals unless these had
undergone predictive testing.

levels in duplicates by single molecule array (Simoa) technique on the Simoa HD-1 Analyzer (Quanterix, Lexington, MA, USA), using the NF-light Advantage kit for
NfL13 and the pNF-heavy Discovery kit (Quanterix) for
pNfH quantiﬁcation,14 according to the manufacturer’s
instructions (dilution: 1/4). For NfL, all measurements
had a coefﬁcient of variation (CV) below 20%. For pNfH,
measurements with CV values above 20% (n = 21) were
excluded to ensure comparable quality. For both analytes,
concentrations were in the previously established range of
quantiﬁcation.13,14 Both NfL and pNfH showed high
technical and intraindividual biological stability (Tables 2
and 3, Fig 5). Technicians were blinded to the genotypic
and clinical status of the samples. Longitudinal samples
were measured in the same batch.
Volumetric brain imaging
For quantiﬁcation of global and frontal brain atrophy,
whole-brain grey matter volume and regional volumes
were quantiﬁed by semi-automated segmentation
methods, based on T1-weighted volumetric magnetic resonance imaging (MRI) scans, and grey matter volumes
were expressed as percentages of total intracranial volume,
as previously described.17
Statistical analysis
We used Mann–
Whitney U tests (2-sided, signiﬁcance level: p < 0.05,
Bonferroni-corrected within each biomarker) to compare
neuroﬁlament baseline levels among clinical states (ie,
presymptomatic carriers, converters, symptomatic carriers,
and controls) and among groups of different disease severity in the early disease stages (unaffected carriers: CDR
plus NACC FTLD = 0, mildly affected carriers: CDR
plus NACC FTLD = 0.5, deﬁnitely affected carriers:
CDR plus NACC FTLD ≥ 1, and controls). To correct
the group effects for the age-related Nf increase observed
in controls,15,20 we calculated the z-score of each subject
in relation to the neuroﬁlament distribution in controls at
the same age.21 For this, the difference between the measured level and the level predicted for controls at the same
age was standardized relative to the distribution in controls at this age. Levels in controls were modeled by linear
regression on the level of log-transformed data. Wherever
possible, we report the effect size r for the applied test.
Baseline

levels

of

neuroﬁlaments.

To capture the
temporal dynamics of neuroﬁlament levels within each subject, we calculated the individual annualized change rate
(for all subjects for whom longitudinal neuroﬁlament measurements were available, n = 196) as the regression coefﬁcient of individual linear regressions of the neuroﬁlament
Annualized change rates of neuroﬁlaments.

Neuroﬁlament quantiﬁcation
Blood samples were centrifuged (2,000 g, 10 minutes, at
room temperature). Serum was frozen at 80  C within
3 hours after collection, shipped and analyzed without any
previous thaw–freeze cycle. We measured neuroﬁlament
January 2022
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TABLE 1. Cohort Characteristics at Baseline

Age
(years)

MMSE

CDR
plus
NACC
FTLD

37%

41.2 (33.2–50.5)

30 (29–30)

0 (0–0)

2.15 (1.30–2.87)

36%

42.5 (33.7–52)

30 (29–30)

0 (0–0)

35

1.10 (1.01–2.27)

39%

41.2 (33.8–50.7)

30 (30–30)

0 (0–0)

34

14

1.98 (1.12–2.16)

35%

36 (31.9–45.9)

30 (30–30)

0 (0–0)

Converter

7

6

1.68 (1.11–2.45)

71%

62.5 (52.2–65.6)

30 (29–30)

0 (0–0)

- C9orf72

6

5

2.08 (1.28–2.57)

67%

57.9 (51.7–63.5)

30 (30–30)

0 (0–0)

- GRN

1

1

1.03

67.8

28

0

Symptomatic

91

38

1.13 (0.99–1.77)

58%

63.3 (57.6–68.4)

25 (19–27)

- C9orf72

47

20

1.22 (1.00–1.91)

66%

64.6 (57.5–70.2)

- GRN

29

12

1.02 (0.97–1.08)

48%

63.4 (59–68.1)

- MAPT

15

6

2.04 (1.76–2.19)

53%

174

78

1.18 (1.02–2.23)

43%

Subjects

Subjects
with
longitudinal
samples

Follow-up
duration
(years)

172

74

1.42 (1.03–2.47)

- C9orf72

64

25

- GRN

74

- MAPT

Group
presymptomatic

Non-carriers

Male
sex

100%

Disease
onset
(years)

Disease
duration
(years)

2 (1–3)

57 (53–63)

4.4 (2.5–6.4)

26 (23–28)

2 (1–3)

57 (53–63)

5.4 (3–7.2)

22 (14–26)

2 (1–3)

60 (55–65)

2.7 (1.9–4.9)

62.5 (55.7–65.1)

24 (19–28)

2 (2–3)

54 (46–59)

6.0 (3.3–8.5)

44.1 (36.6–55.2)

30 (29–30)

0 (0–0)

The clinical phenotype of symptomatic mutation carriers was behavioral variant FTD (n = 60), primary progressive aphasia (n = 16), amyotrophic lateral sclerosis (n = 7), frontotemporal dementia with amyotrophic lateral sclerosis (n = 3), corticobasal syndrome (n = 2), progressive supranuclear palsy
(n = 1), and dementia not otherwise speciﬁed (n = 2). For converters, the age at conversion was 65.7 (54.7–67.4) years. The global follow-up duration
across all subjects with longitudinal samples was 1.19 (1.02–2.23) years. Data are reported as median and interquartile range.
CDR plus NACC FTLD = Clinical Dementia Rating scale plus FTLD modules; MMSE = Mini-Mental State Examination.

level over age. The annualized change rates were compared
between clinical states with Mann–Whitney U tests
(as speciﬁed above).
Linear mixed-effects models. To characterize the disease
stages of genetic FTD in terms of both neuroﬁlament
levels and their change rates, we used linear mixed-effects
models of longitudinal neuroﬁlament data, thus considering the covariance between repeated measurements of each
subject.16,22 In the models, we included clinical status
(presymptomatic stage, conversion stage, symptomatic
stage, and controls as the reference group), age (centered
at the mean baseline age of all subjects), and time from
baseline (ie, the ﬁrst serum sample) as ﬁxed effects, the
interaction of clinical status and time from baseline, and
the random variable subject, modeled by random intercepts (R packages: lme4 and effects). The addition of random slopes did not improve the model ﬁt. Neuroﬁlament
levels were log-transformed to meet the models’
assumptions.
Biomarker cascade model. To assess the dynamics of
biomarker changes in terms of timing and effect size
uniformly across several biomarkers, we modeled the
normalized baseline biomarker values (as z-score) over

36

age with polynomials and compared the predicted
values of carriers with those of controls at the same age
(as z-score difference).23,24 For each biomarker, the biomarker values (log-transformed for both NfL and
pNfH) were normalized relative to their distribution in
controls (ie, transformed to z-scores). The z-scores were
modeled with orthogonal polynomials over age, separately for carriers and controls to allow different dynamics between groups. Higher-order polynomial terms
were included if signiﬁcant (max. cubic terms). The
model predictions for carriers were compared to the
predictions for controls at the same age by calculating
the z-score difference. We applied this approach to all
mutation carriers together and, additionally, to the
three genetic groups separately, allowing exploration
also of gene-speciﬁc biomarker cascades.
Sample size estimation for intervention trials. We estimated stage-dependent sample sizes for future treatment
trials using the reduction of neuroﬁlament levels
towards the levels observed in healthy controls as outcome measure.21,25 We estimated the total sample size
required to detect a given control-adjusted relative
reduction of neuroﬁlament levels (20–80%) in the
treatment arm, assuming that null mean change over
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TABLE 2. Within- and Between-run Precision of the
NfL and pNfH Assay

Analyte

Mean
concentration
(pg/ml)

Within-run
precision
(%)

Between-run
precision (%)

NfL

6.2

7.5

9.7

NfL

19.0

3.3

3.6

NfL

36.6

7.1

6.0

pNfH

84.4

3.6

5.5

pNfH

23.9

6.2

13.5

pNfH

235.5

4.0

6.1
44

Within-run precision and between-run precision were derived from
4 consecutive runs of the same biological sample, using 3 samples
with different analyte concentrations.
NfL = neuroﬁlament light; pNfH = phosphorylated neuroﬁlament
heavy.

time occurred in the placebo arm of the trial. We based
the assumed intersubject variability in the hypothetical
trial on the measured intrasubject variability in the
change of analyte levels (from baseline to ﬁrst followup) in our mutation carriers. The estimation further
assumed equal numbers of subjects in both study arms
(ie, allocation ratio 1:1), α = 0.05, β = 0.05, 2-tailed
independent t tests, and the use of log-transformed biomarker levels. It was performed with GPower version
3.1 software (Kiel, Germany). We also explored the
sample size which would be required for trials aiming to
normalize the increased annualized change rates of NfL
during the conversion stage (instead of reducing its
absolute levels), using the standardized response mean
in analogy to approaches in other neurodegenerative
diseases.26

Data availability
The de-identiﬁed data of this article can be accessed on
reasonable request addressed to the GENFI consortium.

Results
NfL and pNfH levels are increased at the
symptomatic, but not the presymptomatic stage
Baseline levels of serum NfL in symptomatic carriers
(38.7 pg/ml [23.7–60.0]) were signiﬁcantly higher than in controls (6.6 pg/ml [4.8–9.6]; p < 0.001, effect size: r = 0.74;
Fig 1A and B). NfL levels in symptomatic carriers were signiﬁcantly increased also in comparison to presymptomatic carriers
(6.8 pg/ml [4.8–9.0], p < 0.001, r = 0.76), whereas NfL levels
of presymptomatic carriers did not differ signiﬁcantly from
those of controls (not signiﬁcant [ns.], r = 0.01). Similarly, also
baseline levels of serum pNfH were signiﬁcantly higher in
symptomatic carriers (156.0 pg/ml [82.9–399.0]) than in both
controls (47.6 pg/ml [23.7–105.6], p < 0.001, r = 0.47) and
presymptomatic carriers (40.7 pg/ml [20.1–93.2], p < 0.001,
r = 0.51), whereas pNfH levels of presymptomatic carriers did
not differ signiﬁcantly from those of controls (ns., r = 0.06;
Fig 1C and D). The increase of neuroﬁlament levels from the
presymptomatic to the symptomatic stage was quantitatively
more pronounced for NfL than for pNfH, as evidenced by its
respective effect sizes (NfL: r = 0.76, and pNfH: r = 0.51).
The results were conﬁrmed if corrected for the age-related neuroﬁlament increase observed in controls (NfL: symptomatic vs.
controls: p < 0.001, r = 0.68, symptomatic vs. presymptomatic: p < 0.001, r = 0.65, presymptomatic vs. controls: ns.,
r = 0.10; pNfH: symptomatic vs. controls: p < 0.001, r =
0.28, symptomatic vs. presymptomatic: p < 0.001, r = 0.29,
presymptomatic vs. controls: ns., r = 0.02). Moreover, the
increases of NfL and pNfH levels from the presymptomatic to
the symptomatic stage were both conﬁrmed within each of the
three genetic subgroups (Fig 1E and F).

TABLE 3. Intra-individual Stability of NfL and pNfH Levels in Mutation Carriers and Controls
Subject group

NfL

pNfH

Sampling interval (years)

Overall

0.947 (0.930–0.960)

0.947 (0.930–0.961)

1.07 (1.00–1.19)

Controls

0.845 (0.768–0.899)

0.940 (0.906–0.962)

1.07 (1.00–1.19)

Presymptomatic carriers

0.834 (0.749–0.892)

0.943 (0.909–0.964)

1.09 (1.01–1.21)

Symptomatic carriers

0.922 (0.857–0.959)

0.903 (0.814–0.950)

1.05 (0.98–1.14)

We assessed the intra-individual stability of neuroﬁlament levels by calculating the intraclass correlation coefﬁcient (ICC) of each analyte (model:
2-way mixed, single measures, absolute agreement, implemented in the R package irr), using the longitudinal neuroﬁlament data (log-transformed) of
subjects’ baseline and ﬁrst follow-up visit (74 presymptomatic, 38 symptomatic, and 78 control subjects). The table reports the ICC estimates with
95% conﬁdence intervals and the sampling interval (median and IQR).
IQR = intequartile range; NfL = neuroﬁlament light; pNfH = phosphorylated neuroﬁlament heavy.
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FIGURE 1: NfL and pNfH levels at the presymptomatic, conversion, and symptomatic stage of genetic FTD. Serum levels of NfL (A, B) and
pNfH (C, D) were measured in FTD mutation carriers at the presymptomatic (green), conversion (orange), and symptomatic disease stage
(red), and in mutation-negative controls (blue). For masking purposes, a jitter was added to subjects’ age (A, C), whereas analyses were
done on raw data. Boxes visualize median, lower, and upper quartiles, whiskers extend to data within 1.5IQR of the median, and dots
represent individual values. Stages were compared with Mann–Whitney U tests (*** p < .001, ns p ≥ .05, two-tailed, Bonferronicorrected). For each of the three genetic subgroups (E), baseline NfL levels were signiﬁcantly higher in symptomatic than
presymptomatic carriers (C9orf72: p < 0.001, r = 0.76, GRN: p < 0.001, r = 0.72, MAPT: p < 0.001, r = 0.76). For reference, baseline
levels of controls are indicated by blue horizontal lines (median with IQR). In addition, baseline pNfH levels were signiﬁcantly higher in
symptomatic than presymptomatic carriers for each of the three subgroups (F) (C9orf72: p < 0.001, r = 0.53, GRN: p < 0.001, r = 0.51,
MAPT: p = 0.009, r = 0.43, post hoc tests corrected for multiple comparisons). IQR = interquartile range; NfL = neuroﬁlament light;
pNfH = phosphorylated neuroﬁlament heavy.
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NfL levels are increased at the conversion stage,
whereas pNfH levels are still normal
Those presymptomatic mutation carriers who developed
symptomatic disease during the longitudinal follow-up (termed converters) showed signiﬁcantly higher baseline levels of
NfL (20.3 pg/ml [13.1–30.6]) than non-converting presymptomatic carriers (6.8 pg/ml [4.8–9.0], p < 0.001, r =
0.27; see Fig 1A and B), indicating that the NfL increase in
genetic FTD precedes the transition from the presymptomatic to the symptomatic disease stage. NfL levels
hereby accurately distinguished converters from nonconverting presymptomatic carriers (area under the curve
[AUC] = 0.91 [0.80–1.00], estimate and 95% conﬁdence
interval), indicating that NfL levels allow predicting future
conversion. In contrast, baseline levels of pNfH were not signiﬁcantly higher in converters (57.7 pg/ml [28.0–112.5])
than in presymptomatic carriers (40.7 pg/ml [20.1–93.2],
ns., r = 0.06; see Fig 1C and D). Each of these ﬁndings was
conﬁrmed if corrected for age-related neuroﬁlament increases
(NfL: converters vs. presymptomatic: p = 0.009, r = 0.21,
pNfH: converters vs. presymptomatic: ns., r = 0.05). Thus,

the conversion stage was marked by increased NfL levels in
combination with still normal pNfH levels.
Individual change rates of neuroﬁlament levels
are increased at the conversion stage for NfL,
and at the symptomatic stage for pNfH
In the group of converters, we observed an intra-individual
longitudinal increase of NfL levels with proximity to the
onset of the symptomatic disease stage (Fig 2A). Accordingly,
the annualized change rate of NfL levels was signiﬁcantly
higher in converters (7.20 pg/[mlyear], 4.70–10.19]) than
in presymptomatic carriers (0.25 pg/[mlyear], [ 0.27–
0.87]; p < 0.001, r = 0.40), indicating an intra-individual
increase of NfL levels in subjects during the conversion stage
(see Fig 2B). The annualized change rate of NfL levels did
not differ signiﬁcantly between presymptomatic carriers and
controls (0.13 pg/[mlyear], [ 0.66–0.65], ns., r = 0.10),
nor between presymptomatic and symptomatic carriers
(1.18 pg/[mlyear], [ 1.88–13.20], ns., r = 0.12), suggesting that intra-individual NfL levels might be stable at
normal levels at the presymptomatic stage and, after the

FIGURE 2: Individual longitudinal trajectories and stage-dependent longitudinal dynamics of NfL and pNfH levels in genetic
FTD. For mutation carriers converting from the presymptomatic to the symptomatic stage (converters), the individual
longitudinal trajectories of NfL (A) and pNfH levels (D) are plotted over the time from the clinically observed disease onset,
with negative time values corresponding to the presymptomatic stage. The dashed line marks the upper quartile of baseline
neuroﬁlament levels in non-converting presymptomatic mutation carriers. The individual annualized change rates of NfL
(B) and pNfH levels (E) were estimated by individual linear regressions for mutation carriers at the presymptomatic ( green),
conversion (orange), and symptomatic stage (red), and for controls (blue). Boxes visualize median, lower, and upper
quartiles, whiskers extend to data within 1.5IQR of the median, and dots represent individual values. For improved
readability, two extreme outliers of the pNfH change rate at the symptomatic stage ( 586 pg/[mlyear], +662 pg/[mlyear])
are not displayed. Stages were compared with Mann–Whitney U tests (*** p < .001, * p < .05, ns p ≥ .05, two-tailed,
Bonferroni-corrected). We modeled the longitudinal neuroﬁlament levels for NfL (C) and pNfH (F) in relation to time from
baseline, clinical state (ie, presymptomatic carrier, converter, symptomatic carrier, and control) and age at baseline, using
linear mixed-effects models. The ﬁgures display the model predictions at mean baseline age, with shaded areas
representing 95% conﬁdence intervals. IQR = interquartile range; NfL = neuroﬁlament light; pNfH = phosphorylated
neuroﬁlament heavy.
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conversion stage, stable at increased levels at the symptomatic
stage (see Fig 2B). NfL change rates accurately distinguished
converters from non-converting carriers (AUC = 0.94
[0.83–1.00]). For pNfH, the change rate was signiﬁcantly
higher in symptomatic carriers (16.40 pg/[mlyear], 3.86–
58.40]) than in presymptomatic carriers (1.28 pg/[mlyear],
[ 2.93–7.52], p = 0.018, r = 0.27; see Fig 2D and E), but
did not differ signiﬁcantly between presymptomatic subjects
and converters (12.83 pg/[mlyear], [7.35–26.34], ns.,
r = 0.23), nor between presymptomatic subjects and
controls (0.83 pg/[mlyear], [ 4.25–15.06], ns., r = 0.05),
suggesting that pNfH levels might remain stable during the

presymptomatic and conversion stage, but – unlike NfL
levels – increase at the symptomatic stage.
Modeling the disease stages of genetic FTD in
terms of NfL and pNfH levels and their change
rates
To comprehensively characterize the disease stages in terms of
both neuroﬁlament levels and their change rates, a linear mixedeffects model was calculated, allowing to integrate all longitudinal
follow-up neuroﬁlament measurements and intraindividual
changes as well as to correct for baseline age. The variable time
from baseline hereby allowed estimation of a regression

FIGURE 3: Biomarker cascade of NfL, pNfH, and volumetric MRI changes across the early CDR stages of genetic FTD. (A) To
assess the relative timing and effect size of biomarker changes uniformly for each biomarker (NfL, pNfH, global brain volume,
and frontal brain volume), we modeled the normalized biomarker values as polynomial functions of subjects’ age and compared
the model predictions for carriers to the model predictions for controls at the same age, calculating the z-score difference.
Increases of the z-score difference towards positive values indicate that the biomarker values become more pathological in the
mutation carrier group (ie, increases of neuroﬁlament levels and decreases of brain volumes), whereas a z-score difference of
zero indicates that the respective biomarker values do not differ between mutation carriers and controls. For each biomarker,
the conﬁdence interval is displayed by dotted lines. The colored vertical lines indicate the baseline age (median and IQR) of
mutation carriers grouped by disease severity (unaffected carriers: CDR plus NACC FTLD = 0, mildly affected carriers: CDR plus
NACC FTLD = 0.5, and deﬁnitely affected carriers CDR plus NACC FTLD ≥ 1), as observed in the present cohort. (B–D) The same
modeling approach was analogously applied to the three genetic groups of mutation carriers (B: C9orf72, C: GRN, and D: MAPT)
to explore gene-speciﬁc dynamics and effect sizes of the biomarker cascade. CDR = Clinical Dementia Rating; FTD =
frontotemporal dementia; IQR = interquartile range; MRI = magnetic resonance imaging; NfL = neuroﬁlament light; pNfH =
phosphorylated neuroﬁlament heavy.

40

Volume 91, No. 1

15318249, 2022, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ana.26265 by Cochrane Canada Provision, Wiley Online Library on [25/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

ANNALS of

coefﬁcient reﬂecting the biomarker annual change rate, whereas
its interaction with the variable clinical state allowed capturing
differences in the annual change rates between clinical states. The
model showed a signiﬁcant effect of subjects’ clinical status on
NfL levels (p < 0.001) and a signiﬁcant interaction of time from
baseline with clinical status (p = 0.008; see Fig 2C; Supplement
1 for complete statistical results). Compared with controls, NfL
levels were signiﬁcantly increased in converters (p < 0.001) and
symptomatic carriers (p < 0.001), but not in presymptomatic
carriers (p = 0.631). The annual change rate of NfL levels was
signiﬁcantly increased in converters (p < 0.001), but neither in
presymptomatic (p = 0.377) nor symptomatic carriers (p =
0.854), indicating that the increase of NfL levels occurs at the
conversion stage. For pNfH, the model showed a signiﬁcant
effect of clinical status on pNfH levels (p = 0.021), without signiﬁcant interaction of time from baseline with clinical status
(Fig 2F; Supplement 2). Compared with controls, pNfH levels
were signiﬁcantly increased in symptomatic carriers (p = 0.003),

but not in presymptomatic carriers (p = 0.808) or converters
(p = 0.865), indicating that the pNfH increase is linked to the
symptomatic stage. Thus, the analysis by linear mixed-effects
models further supports the notion that the combined temporal
dynamics of both neuroﬁlament types might allow demarcating
the conversion stage: its onset is marked by increased NfL levels
and NfL change rates (but still normal pNfH levels), whereas its
completion with transition to the symptomatic stage is marked
by increased pNfH levels.
Modeling the multimodal biomarker cascade of
genetic FTD: NfL increase concurs with brain
atrophy onset, while pNfH increase starts close
to clinical onset – with varying temporal
dynamics and effect sizes in the three genetic
FTD groups
To further assess the temporal dynamics of each biomarker (NfL, pNfH, global and frontal brain volume), we

FIGURE 4: Stratiﬁcation of the early stages of disease severity in genetic FTD by NfL and pNfH levels. Baseline levels of NfL (A) and
pNfH (C) were compared between unaffected carriers (CDR plus NACC FTLD = 0), mildly affected carriers (CDR plus NACC FTLD = 0.5),
deﬁnitely affected carriers (CDR plus NACC FTLD ≥ 1) and controls. To take into consideration the age-related increase of neuroﬁlament
levels, the absolute levels (A, C) were corrected for the age-related increase observed in controls by z-transformation (B, D). Boxes
visualize median, lower, and upper quartiles, whiskers extend to data within 1.5IQR of the median, and circles represent individual
values. Baseline values of converters are marked by circles ﬁlled with grey. Groups were compared with Mann–Whitney U tests (***
p < .001, ** p < .01, * p < .05, ns p ≥ .05, 2-tailed, Bonferroni-corrected). CDR = Clinical Dementia Rating; FTD = frontotemporal
dementia; IQR = interquartile range; NfL = neuroﬁlament light; ns. = not signiﬁcant; pNfH = phosphorylated neuroﬁlament heavy. [Color
ﬁgure can be viewed at www.annalsofneurology.org]
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used polynomials to model the normalized biomarker
values (z-scores) over age and compared the predicted biomarker values of mutation carriers to those of controls at
the same age (Fig 3A). The z-score difference allowed capturing timing and effect size of biomarker changes uniformly across all biomarkers. In this biomarker cascade,

the NfL z-score difference started to increase at age
42 years (as indicated by the time at which the 95% conﬁdence interval of the z-score difference ceases to overlap
zero), thus preceding the observed clinical onset at age
57 years (53–63 years) by approximately 15 years. In contrast, the pNfH z-score difference started to increase at age

FIGURE 5: Within-subject stability of neuroﬁlament levels and stage-dependent sample size estimates for intervention trials in
genetic FTD. The intra-individual stability of NfL (A) and pNfH (B) serum levels from baseline to ﬁrst follow-up was assessed in
presymptomatic and symptomatic carriers and control subjects. Lines link data of the same individuals. Sample size estimations
(C) were performed for hypothetical intervention trials using the reduction of neuroﬁlament levels as outcome measure, taking
into consideration the disease stage. The estimated total sample size (ie, sum of subjects in both study arms) is plotted over the
assumed therapeutic effect for lowering the neuroﬁlament level in mutation carriers towards the levels observed in healthy
controls. FTD = frontotemporal dementia; NfL = neuroﬁlament light; pNfH = phosphorylated neuroﬁlament heavy. [Color ﬁgure
can be viewed at www.annalsofneurology.org]
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53 years, close to the observed clinical onset. For both
NfL and pNfH, the z-score difference reached a plateau at
the late symptomatic stage. Analogous analysis showed
that volumetric changes of the global brain volume and
the frontal lobe volume started at age 39 years, thus preceding the observed onset by approximately 18 years. In
summary, the NfL increase in mutation carriers preceded
clinical disease onset and concurred with brain atrophy
onset, whereas the pNfH increase started close to clinical
onset (see Fig 3A). Exploratory analogous modeling in the
3 genetic subgroups of mutation carriers (see Fig 3B–D)
suggested that, in each the C9orf72 and GRN group, an
NfL increase started at the presymptomatic stage (reaching
a pronounced z-score level of abnormality, with NfL effect
sizes in the GRN group larger than those of the MRI measures), followed by a pNfH increase with the onset of the
symptomatic stage (reaching a less pronounced z-score
level of abnormality). In the MAPT group, the NfL
increase (also starting at the presymptomatic stage) was,
however, slower and the pNfH increase appeared absent.
The MRI measures yielded stronger effect sizes than the
NfL increase in the MAPT group (see Fig 3D).
The combination of NfL and pNfH levels allows
stratiﬁcation of FTD disease severity in the early
disease stages
NfL levels were signiﬁcantly increased in both mildly
affected carriers (CDR plus NACC FTLD = 0.5 at baseline visit, p = 0.004, r = 0.21) and deﬁnitely affected carriers (CDR plus NACC FTLD ≥ 1, p < 0.001, r = 0.68),
each compared with controls, whereas unaffected carriers
(CDR plus NACC FTLD = 0) did not show increased
NfL levels (ns., r = 0.03; Fig 4A). This ﬁnding was conﬁrmed if NfL levels were corrected for the age-related
increase observed in controls. The age-corrected NfL zscores were signiﬁcantly increased in both mildly affected
carriers (p = 0.017, r = 0.19) and deﬁnitely affected carriers (p < 0.001, r = 0.62), but not in unaffected carriers
(ns., r = 0.11; see Fig 4B). In contrast, pNfH levels were
increased in deﬁnitely affected carriers (p < 0.001,
r = 0.40), but not in unaffected (ns., r = 0.08) or mildly
affected carriers (ns., r = 0.13; see Fig 4C). Likewise, agecorrected pNfH z-scores were signiﬁcantly increased in
deﬁnitely affected carriers (p < 0.001, r = 0.23), but not
in unaffected (ns., r = 0.03) or mildly affected carriers
(ns., r = 0.08; see Fig 4D). Thus, already ﬁrst mild clinical manifestations were captured by the NfL increase,
whereas the deﬁnite clinical manifestation of FTD was
reﬂected by the combined increase of both NfL
and pNfH.
Add-on analysis suggested that neuroﬁlament levels
in genetic FTD might also correlate with the extent of
January 2022

motoneuron involvement, with differential capture of
upper versus lower motoneuron involvement by NfL and
pNfH (Supplement 3).
Both NfL and pNfH show high technical and
intra-individual biological stability
Technical stability was comparable for NfL and pNfH, as
demonstrated by similarly high within- and between-run
precision (see Table 2). Moreover, biological stability (ie,
intraindividual analyte stability) was comparable for NfL
and pNfH, as evidenced by high intraclass correlation
coefﬁcients of both analytes in longitudinal measurements
(see Table 3, Fig 5A and B).
Neuroﬁlament levels as disease-stagedependent outcome parameters for intervention
trials
We estimated sample sizes for intervention trials using the
reduction of neuroﬁlament levels as outcome parameter,
taking into consideration the respective disease stage of
genetic FTD. Our estimates indicate that, to detect a therapeutic effect size of 50% if using NfL levels, the required
total sample size would be 12 subjects at the symptomatic
stage (for 1:1 randomization, see Fig 5C for visualization
of a range of other possible therapeutic effect sizes) and
18 subjects at the conversion stage. For a more modest
effect size of 30%, 24 subjects at the symptomatic stage
(32 subjects for 3:1 randomization) and 46 subjects at the
conversion stage would be needed. If using pNfH levels as
outcome parameters at the symptomatic stage, 26 subjects
would be needed for an effect size of 50% and 66 subjects
for an effect size of 30%. For intervention trials aiming to
normalize the increased annualized change rates of NfL
during the conversion stage (instead of reducing its absolute levels), our estimates indicate that 88 subjects would
be required.

Discussion
Stratiﬁcation of the presymptomatic phase of genetic FTD
via objective and easily accessible molecular biomarkers is
warranted to pave the way for upcoming targeted treatment trials. Leveraging the longitudinal multicenter
GENFI cohort, we here demonstrate a cascade of biomarker changes in presymptomatic genetic FTD, where
the NfL increase in blood precedes the hypothetical clinical onset by 15 years, here concurring with the onset of
global brain atrophy, followed by a pNfH increase starting
close to clinical onset. Moreover, we demonstrate that
neuroﬁlament levels allow demarcating the conversion
stage, for which the onset is marked by increased levels
and intra-individual change rates of NfL (but still normal
pNfH levels), and its completion with transition to the
43

15318249, 2022, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ana.26265 by Cochrane Canada Provision, Wiley Online Library on [25/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Wilke et al: Stratifying Presymptomatic FTD by NfL and pNfH

Neurology

symptomatic stage by increased pNfH levels. Thus, NfL
and pNfH levels might provide disease stage-dependent
stratiﬁcation biomarkers and, possibly, treatment outcome
biomarkers in genetic FTD.
Our study suggests an association of the onset of the
NfL increase to the conversion stage, given that both NfL
levels and NfL increase rates were increased in presymptomatic carriers converting to symptomatic disease,
but not in carriers remaining presymptomatic during longitudinal follow-up. The NfL increase preceded the mean
clinical onset observed in the symptomatic subjects of our
cohort by 15 years, thus even earlier than estimated in
previous studies.16 Moreover, as the NfL increase concurred with the onset of both global and frontal brain
atrophy (see Fig 3A), it might serve as an easily accessible
and early peripheral blood readout for incipient centralnervous brain degeneration. Taken together, these ﬁndings
do not merely conﬁrm blood NfL as a biomarker altered
already early in the course of genetic FTD,16,27 but provide a more ﬁne-grained picture of its dynamics during
the presymptomatic phase of the disease.
Moreover, our study now complements these ﬁndings on the dynamics of NfL with the dynamics of pNfH.
It associates the onset of the pNfH increase with the onset
of the symptomatic stage, as pNfH levels and pNfH
change rates were increased in symptomatic, but not yet
in presymptomatic or converting carriers. Correspondingly, modeling of the biomarker cascade showed that the
pNfH increase occurred close to clinical onset. Thus, conﬁrming and extending the earlier result of a cross-sectional
piloting study,14 our study suggests that the pNfH
increase might serve as a biomarker in the symptomatic
phase of genetic FTD, paralleling ﬁndings from other
multisystemic neurodegenerative diseases where pNfH
increases were linked to later disease stages.21 Thus, the
combination of both biomarkers – NfL and pNfH –
might be clinically relevant in the early and late stages of
neurodegenerative diseases.28
Although neuroﬁlament increases are speciﬁc in that
they signal axonal decay rate (rather than merely
unspeciﬁc cell damage), their value in genetic FTD does
not primarily consist in their use as diagnostic biomarkers,
as neuroﬁlament levels are increased in various neurodegenerative
and
non-neurodegenerative
conditions12,14,21,22,29–31 and as assessment of mutations and
altered disease-speciﬁc proteins already meets such a diagnostic purpose.32–34 For preparing future FTD intervention trials, however, the biomarker value of neuroﬁlament
levels rather consists in their potential use as stratiﬁcation,
disease severity, and treatment response biomarkers. Particularly, our ﬁndings indicate that – as stratiﬁcation biomarkers – neuroﬁlament levels might allow demarcating
44

the conversion stage, for which the onset is marked by
increased NfL levels and NfL change rates (but still normal pNfH levels) and its completion (with transition to
the symptomatic stage) by increased pNfH levels. The
combined use of NfL and pNfH levels as stratiﬁcation
biomarkers might thus help optimizing the selection of eligible mutation carriers for clinical trials, if one assumes
that future disease-modifying therapies might be most
effective in a window of opportunity immediately before
clinical onset. Such fully biomarker-based stratiﬁcation
appears relevant as the age of onset in genetic FTD currently cannot be reliably predicted on the basis of the
familial age of onset.17,35 NfL might even quantitatively
capture proximity-to-onset as individual NfL levels of converters continuously increased with proximity to the individually observed clinical onset.
Neuroﬁlament levels – and in particular NfL –
might moreover serve as biomarkers of disease severity in
the early phases of genetic FTD, as evidenced by their
increase with increasing CDR plus NACC FTLD levels in
these early phases. Whereas still normal at CDR stage
0, they progressively increase with the CDR stages 0.5
and >0.5. They then seem to reach a plateau, where these
increased levels are maintained, indicating a stable rate of
increased axonal decay at CDR stages >0.5 (see Figs 2C
and 3A). Our ﬁndings thus expand and specify previous
research reporting an association of NfL levels with FTD
disease severity.36 Moreover, our ﬁndings on the differential associations of NfL versus pNfH levels with upper versus lower motoneuron involvement (Supplement 3) –
although still preliminary given the small sample size – are
compatible with and extend previous ﬁndings suggesting
that both NfL and pNfH correlate with the degree of clinical upper and lower motoneuron involvement,37 but with
pNfH levels correlating better with lower motoneuron
affection and NfL levels better with upper motoneuron
affection.37,38
Our study provides ﬁrst sample size estimates for
future trials of disease-modifying treatments using neuroﬁlament levels as treatment response biomarkers. Intraindividual biological variation is likely only a minimal
source of noise when using neuroﬁlament blood levels as
outcome measure, as our study shows that levels of each
NfL and pNfH are highly stable within individuals, as
demonstrated by the high intraclass correlation coefﬁcients
in mutation carriers, assessed over ≈12 months (see
Table 3), with biological stability not varying with age
(Supplement 4). Using neuroﬁlament levels as outcome
parameters might thus help to reduce trial sample sizes in
comparison to clinical outcome measures. Indeed, our
sample size estimates for trials aiming to lower absolute
NfL blood levels in genetic FTD indicate that a total
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sample size of 12 subjects would sufﬁce to detect therapeutic effect sizes of 50% (24 subjects for a more modest
therapeutic effect size of 30%), if using NfL at the symptomatic stage. Importantly, our study demonstrates that
the sample size estimates need to be stage-speciﬁc: If using
NfL as outcome parameter at the conversion stage, a
higher sample size of 18 subjects would be required for
detecting the same therapeutic effect size, which is
explained by quantitatively smaller increase of NfL levels
at the conversion stage in comparison to the symptomatic
stage.
Thus, whereas our ﬁndings show a higher sensitivity
of NfL to capture the onset of the neurodegenerative process at the conversion stage, both analytes might be
explored further in combination in future FTD natural
history and treatment trials, given (1) the signiﬁcant
increase and high intraindividual stability of both NfL and
pNfH, (2) their potential to demarcate the onset and the
completion of the conversion phase, respectively, and
(3) the possibility that they might yield differential
responses and dynamics in response to therapeutic interventions or reﬂect different features of the disease process,
as suggested for other neurodegenerative diseases.39–41
Our study has several limitations. First, although we
demonstrate that the later increase of pNfH relative to
NfL levels is not due to differences in the technical and
biological stability of both analytes, this effect might in
part be explained by the smaller effect size of the pNfH
increase. Therefore, further studies are warranted to scrutinize the differential cellular mechanisms and dynamics
underlying NfL and pNfH increases in genetic FTD. A
recent report already provides a ﬁrst hint to an underlying
biological difference: by the example of ALS, it suggests a
metabolic shift from NfH expression to less energy consuming NfL expression in neurons of neurodegenerative
disease patients.42 Such an altered metabolic proﬁle of
neurons exposed to neurodegeneration, with altered
energy demands, might possibly explain the stage speciﬁc
increase in NfL versus pNfH, which we observe here. Second, although the genetic subgroups of our study were
sufﬁciently powered to conﬁrm at least one of the main
ﬁndings in each genetic subgroup (the increase of NfL
and pNfH levels from the presymptomatic to the symptomatic stage, see Fig 1E and F), larger longitudinal
cohort sizes per gene would be required to run such subgroup analyses also for the other ﬁndings, particularly for
the key ﬁndings related to change rates, the converting
subjects, and the temporal proximity of the biomarker
changes to the hypothetical clinical onset. Although our
study links the onset of the NfL increase clearly to the
beginning of the conversion stage and the pNfH increase
to the symptomatic stage of genetic FTD, ﬁrst incipient
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biological changes of pNfH levels during the conversion
stage might possibly be captured with a substantially larger
number of converters. Third, we used age as a proxy measure for the approaching symptom onset, like other studies, because no better proxy is currently available in
genetic FTD and because the known high variation of
onset age within families35 would render analyses based
on the average family onset age a possible source of uncertainty or bias. Fourth, the proposed preliminary biomarker
cascade may require further gene-speciﬁc adjustments in
larger genetic subcohorts, given the quantitative and qualitative differences observed here in the neurodegenerative
process of each genetic group (see Fig 3B–D), also ideally
integrating additional biomarker modalities into the cascade framework. Finally, our ﬁndings require validation in
independent longitudinal genetic FTD cohorts, like the
ALLFTD cohort.43
In conclusion, our longitudinal study shows that
blood NfL and pNfH provide stage-dependent stratiﬁcation and, potentially, treatment response biomarkers in
presymptomatic FTD, allowing demarcation of the conversion stage. The proposed preliminary biomarker cascade of NfL, pNfH, and volumetric MRI brain changes
might help pave the way towards a biomarker-based precision medicine approach to genetic FTD, supporting the
multimodal stratiﬁcation of the presymptomatic phase.
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